{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:15:32Z","timestamp":1792613732198,"version":"4.5.0"},"reference-count":39,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Obesity has emerged as a widespread disease with epidemic proportions, necessitating effective management to enhance the overall health outcomes of patients. Medical intervention for weight loss becomes necessary when diet and exercise prove ineffective, and topiramate emerges as a potential treatment option for this global problem. Currently approved as an anti-epileptic and migraine prophylaxis medication, topiramate is frequently utilized as adjunctive therapy for patients with mood and eating disorders, as well as for alcohol use disorders. Its multifaceted mechanisms of action contribute to reducing neuronal excitation and enhancing neuronal inhibition. Given its variety of mechanisms, topiramate shows several off-label outcomes, including weight loss, for patients prescribed this medication. Although the specific mechanism of action concerning weight loss remains uncertain, various hypotheses have been reported. Notably, topiramate may contribute to weight loss by reducing calorie intake, decreasing fat gain, and lowering triglyceride and cholesterol levels. Additionally, its impact on reward pathways associated with food could play a role. Multiple clinical studies have supported the use of topiramate as a weight-loss medication. Notably, the medication demonstrates effectiveness in reducing body weight across different dosages and sustaining weight loss over time, outperforming alternative weight loss methods. Moreover, it was generally well-tolerated in clinical studies, with few side effects observed. In conclusion, topiramate offers promising potential as a weight loss solution and can be a valuable addition to the range of treatment options for combating obesity.<\/jats:p>","DOI":"10.3390\/life13091845","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T11:33:25Z","timestamp":1693481605000},"page":"1845","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Topiramate (Topamax): Evolving Role in Weight Reduction Management: A Narrative Review"],"prefix":"10.3390","volume":"13","author":[{"given":"Irza","family":"Wajid","sequence":"first","affiliation":[{"name":"School of Medicine, Louisiana State University Health Sciences Center at New Orleans, New Orleans, LA 70112, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Vega","sequence":"additional","affiliation":[{"name":"School of Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Thornhill","sequence":"additional","affiliation":[{"name":"School of Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Jenkins","sequence":"additional","affiliation":[{"name":"School of Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandler","family":"Merriman","sequence":"additional","affiliation":[{"name":"School of Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Chandler","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4545-4523","authenticated-orcid":false,"given":"Sahar","family":"Shekoohi","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7961-3931","authenticated-orcid":false,"given":"Elyse M.","family":"Cornett","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2464-0187","authenticated-orcid":false,"given":"Alan D.","family":"Kaye","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA"},{"name":"Department of Pharmacology, Toxicology, and Neurosciences, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA 71103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/2327-6924.12510","article-title":"Obesity: Risk factors, complications, and strategies for sustainable long-term weight management","volume":"29","author":"Fruh","year":"2017","journal-title":"J. Am. Assoc. Nurse Pract."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"167S","DOI":"10.1038\/oby.2004.284","article-title":"Topiramate: A New Potential Pharmacological Treatment for Obesity","volume":"12","author":"Astrup","year":"2004","journal-title":"Obes. Res."},{"key":"ref_3","unstructured":"Fariba, K.A., and Saadabadi, A. (2023, July 12). Topiramate, Available online: https:\/\/ncbi.nlm.nih.gov\/books\/NBK554530\/."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2147\/NDT.S512","article-title":"Topiramate in the treatment of partial and generalized epilepsy","volume":"3","author":"Faught","year":"2007","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/00004714-200212000-00010","article-title":"Review of the Use of Topiramate for Treatment of Bipolar Disorders","volume":"22","author":"Suppes","year":"2002","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1528-1157.2000.tb02169.x","article-title":"Topiramate as an inhibitor of carbonic anhydrase isoenzymes","volume":"41","author":"Dodgson","year":"2000","journal-title":"Epilepsia"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Pearl, N.Z., Babin, C.P., Catalano, N.T., Blake, J.C., Ahmadzadeh, S., Shekoohi, S., and Kaye, A.D. (2023). Narrative Review of Topiramate: Clinical Uses and Pharmacological Considerations. Adv. Ther.","DOI":"10.1007\/s12325-023-02586-y"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.metabol.2006.06.013","article-title":"The messenger RNA profiles in liver, hypothalamus, white adipose tissue, and skeletal muscle of female Zucker diabetic fatty rats after topiramate treatment","volume":"55","author":"Liang","year":"2006","journal-title":"Metabolism"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eplepsyres.2011.05.014","article-title":"Topiramate-induced weight loss: A review","volume":"95","author":"Verrotti","year":"2011","journal-title":"Epilepsy Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0899-9007(00)00452-4","article-title":"Influence of topiramate in the regulation of energy balance","volume":"16","author":"Richard","year":"2000","journal-title":"Nutrition"},{"key":"ref_11","unstructured":"Ben-Menachem, E., Axelsen, M., and Johanson, E.H. (2022, July 12). Predictors-of-Weight-Loss-in-Patients-with-Epilepsy-Treated-with-Topiramate. Available online: https:\/\/www.aesnet.org\/abstractslisting\/predictors-of-weight-loss-in-patients-with-epilepsy-treated-with-topiramate."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00228-006-0220-1","article-title":"The effect of topiramate on energy balance in obese men: A 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension","volume":"63","author":"Tremblay","year":"2007","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1126\/science.289.5487.2122","article-title":"Role of brain insulin receptor in control of body weight and reproduction","volume":"289","author":"Gautam","year":"2000","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1210\/en.2012-1272","article-title":"Topiramate treatment improves hypothalamic insulin and leptin signaling and action and reduces obesity in mice","volume":"153","author":"Caricilli","year":"2012","journal-title":"Endocrinology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.schres.2010.02.001","article-title":"Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: A double-blind, placebo-controlled trial","volume":"118","author":"Narula","year":"2010","journal-title":"Schizophr. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/sj.ijo.0803548","article-title":"Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: Randomized double-blind placebo-controlled trial","volume":"31","author":"Eliasson","year":"2007","journal-title":"Int. J. Obes."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"E1015","DOI":"10.1152\/ajpendo.00169.2005","article-title":"Topiramate treatment causes skeletal muscle insulin sensitization and increased Acrp30 secretion in high-fat-fed male Wistar rats","volume":"289","author":"Wilkes","year":"2005","journal-title":"Am. J. Physiol.-Endocrinol. Metab."},{"key":"ref_18","first-page":"1187","article-title":"Topiramate induces weight loss and improves insulin sensitivity in dietary obese rats: Comparison to sibutramine","volume":"15","author":"Zaitone","year":"2011","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1001\/jama.2016.7602","article-title":"Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis","volume":"315","author":"Khera","year":"2016","journal-title":"JAMA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1210\/jc.2014-3421","article-title":"Clinical review: Drugs commonly associated with weight change: A systematic review and meta-analysis","volume":"100","author":"Domecq","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","article-title":"The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: An unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: An unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1001\/archneur.62.11.1705","article-title":"Topiramate in Patients With Juvenile Myoclonic Epilepsy","volume":"62","author":"Biton","year":"2005","journal-title":"Arch. Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00415-004-0464-6","article-title":"Topiramate in migraine prophylaxis: Results from a placebo-controlled trial with propranolol as an active control","volume":"251","author":"Diener","year":"2004","journal-title":"J. Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archneur.61.4.490","article-title":"Topiramate in Migraine Prevention: Results of a Large Controlled Trial","volume":"61","author":"Silberstein","year":"2004","journal-title":"Arch. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e1809","DOI":"10.1097\/MD.0000000000001809","article-title":"Efficacy and Safety of Topiramate for Essential Tremor: A Meta-Analysis of Randomized Controlled Trials","volume":"94","author":"Chang","year":"2015","journal-title":"Medicine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s40263-015-0244-0","article-title":"Topiramate in Alcohol Use Disorders: Review and Update","volume":"29","author":"Guglielmo","year":"2015","journal-title":"CNS Drugs"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/head.12997","article-title":"Topiramate in Migraine Prevention: A 2016 Perspective","volume":"57","author":"Silberstein","year":"2017","journal-title":"Headache J. Head Face Pain"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/oby.2003.102","article-title":"A 6-Month Randomized, Placebo-Controlled, Dose-Ranging Trial of Topiramate for Weight Loss in Obesity","volume":"11","author":"Bray","year":"2003","journal-title":"Obes. Res."},{"key":"ref_30","first-page":"297","article-title":"The effect of topiramate on weight loss in patients with type 2 diabetes","volume":"18","author":"Moradi","year":"2013","journal-title":"J. Res. Med. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/sj.ijo.0803382","article-title":"Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: A randomized, double-blind, placebo-controlled study","volume":"31","author":"Toplak","year":"2007","journal-title":"Int. J. Obes."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/oby.2003.78","article-title":"Predictors of weight loss in adults with topiramate-treated epilepsy","volume":"11","author":"Axelsen","year":"2003","journal-title":"Obes. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/oby.2004.206","article-title":"Topiramate: Long-Term Maintenance of Weight Loss Induced by a Low-Calorie Diet in Obese Subjects","volume":"12","author":"Astrup","year":"2004","journal-title":"Obes. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.amjcard.2005.03.053","article-title":"Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension","volume":"96","author":"Tonstad","year":"2005","journal-title":"Am. J. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/sj.ijo.0802783","article-title":"A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects","volume":"28","author":"Wilding","year":"2004","journal-title":"Int. J. Obes."},{"key":"ref_36","first-page":"446","article-title":"Phentermine\/Topiramate extended-release capsules (qsymia) for weight loss","volume":"38","author":"Lonneman","year":"2013","journal-title":"Pharm. Ther."},{"key":"ref_37","first-page":"131","article-title":"Clinical utility of phentermine\/topiramate (Qsymia\u2122) combination for the treatment of obesity","volume":"6","author":"Shin","year":"2013","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s13556-012-0003-1","article-title":"A Review of the Combination of Phentermine and Topiramate Extended-Release for Weight Loss","volume":"2","author":"Steffen","year":"2012","journal-title":"Comb. Prod. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1111\/j.1467-789X.2010.00846.x","article-title":"Efficacy and safety of topiramate on weight loss: A meta-analysis of randomized controlled trials","volume":"12","author":"Kramer","year":"2011","journal-title":"Obes Rev."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/9\/1845\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:43:42Z","timestamp":1760129022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/9\/1845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,31]]},"references-count":39,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["life13091845"],"URL":"https:\/\/doi.org\/10.3390\/life13091845","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,31]]}}}